Key result
Review highlights unresolved uncertainties regarding medical and interventional therapies for CKD patients with ACS.
Why the study?
The clinical management of patients with CKD who develop ACS is problematic due to lack of well-designed randomized trials assessing therapeutic strategies in this population.
This review highlights the critical evidence gap and under-treatment of patients with concurrent CKD and ACS, emphasizing the need for better therapeutic strategies in this high-risk population.
Highlights evidence gap for CKD-ACS management; leaves open optimal strategies pending dedicated RCTs.
Chronic kidney disease (CKD) is highly prevalent in patients with acute coronary syndromes (ACS) and is associated with poor outcomes. The clinical management of patients with CKD who develop ACS is problematic because of the lack of well-designed randomized trials assessing therapeutic strategies in such patients. The almost uniform exclusion of patients with CKD from randomized studies evaluating new targeted therapies for ACS, and concern about further deterioration of renal function and therapy-related toxic effects, may explain the less frequent use of proven medical therapies in this subgroup of high-risk patients. This could contribute to their excessive mortality. The objective of this review is to discuss the unresolved issues and uncertainties regarding recommended medical therapies and interventional strategies in CKD patients who develop an ACS.
No takes yet. Share an insight, caveat, or question.
Marenzi et al. (2006) conducted a review in Acute coronary syndromes and chronic kidney disease. Medical therapies and interventional strategies was evaluated. This review discusses the unresolved issues and uncertainties regarding recommended medical therapies and interventional strategies in chronic kidney disease patients who develop an acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: